Norwalk, CT - January 11, 2024 – LifeSpan Vision Ventures, an investment firm specializing in the aging and longevity space, has announced today an investment into Immunis, Inc as part of a $25 million Series A-1 financing round to fund two Phase 2 clinical trials.
Immunis is developing multi-active biologics to address age-related diseases. Preclinical data of Immunis’ novel therapy in aged mouse models of muscle disuse atrophy and metabolism were published in GeroScience and Aging Cell. The multi-active therapy was shown to reverse muscle atrophy, improve muscle function, enhance metabolism, and decrease fat. Immunis is currently the leading biotech with the most advanced stem cell-derived multi-active biologic in human clinical trials. The team is planning a Phase 2b clinical trial to follow up on the successful Phase 1/2a STEM-MYO clinical trial measuring the safety and tolerability of IMM01-STEM in people with age-related muscle atrophy associated with knee osteoarthritis. Separately, the FDA granted permission to proceed with a parallel Phase 2 STEM-META clinical trial testing the efficacy of IMM01-STEM in ameliorating muscle loss and reversing metabolic dysfunction in sarcopenic, overweight, and obese elderly people.
“We are excited to support Immunis in their upcoming clinical trials in two different elderly populations, building off encouraging signals received in their preliminary data,” says Andrew Worden, Founding Partner at LifeSpan Vision Ventures. “Our investment in Immunis reflects our commitment to supporting teams that are developing therapies that enable healthy lifespan extension.”
“We value investors like LifeSpan Vision Ventures who take an active role in supporting their portfolio companies beyond capital,” says Mark Cabato, Chief Business Officer at Immunis. “LifeSpan Vision Ventures sees the longevity and aging space with a wide lens and has provided us valuable market insights, facilitated introductions, and given critical feedback. We greatly appreciate their support of our mission.”
About Immunis
Immunis, Inc is a clinical-stage biotechnology company based in Irvine, CA developing novel, multi-active biologics for age and disease-related immune dysregulation.
For more information, visit: https://immunisbiomedical.com/home/
About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space.
Contact: Harry Robb, Analyst: harry.robb@lifespanvison.com
Comments